How to Get Farxiga (Dapagliflozin) in Wisconsin

Who Can Prescribe Farxiga in Wisconsin

Any Wisconsin-licensed prescriber with prescriptive authority can write a dapagliflozin prescription. That includes physicians (MD and DO), nurse practitioners, and physician assistants.

Wisconsin NPs gained full practice authority in 2024, which means they can prescribe Farxiga independently without a physician collaborative agreement. PAs still require a supervisory relationship with a physician, per Wisconsin Administrative Code Med 8. Both NPs and PAs routinely prescribe SGLT2 inhibitors in primary care and endocrinology settings across the state.

For patients with heart failure, a cardiologist or heart failure specialist may initiate the prescription. The 2022 AHA/ACC/HFSA heart failure guideline recommends SGLT2 inhibitors as a class I indication for heart failure with reduced ejection fraction, regardless of diabetes status. Wisconsin's academic medical centers, including UW Health in Madison and the Medical College of Wisconsin in Milwaukee, have incorporated dapagliflozin into their standard heart failure treatment pathways.

Nephrologists also prescribe Farxiga for chronic kidney disease (CKD). The drug earned its FDA approval for CKD in April 2021, making it the first SGLT2 inhibitor approved to reduce CKD progression in patients with and without type 2 diabetes.

Telehealth Access to Farxiga in Wisconsin

Wisconsin law permits licensed telehealth providers to prescribe Farxiga after a synchronous audio-video visit. No in-person exam is required for the initial prescription.

The Wisconsin Medical Examining Board allows providers to establish a patient-provider relationship via telehealth, provided the encounter meets the same standard of care as an in-person visit. This applies to both in-state providers and those holding a Wisconsin license through the Interstate Medical Licensure Compact. Wisconsin joined the compact, which means physicians licensed through it can see Wisconsin patients remotely from another state.

A typical telehealth workflow for Farxiga looks like this: the patient submits recent lab results (fasting glucose, HbA1c, eGFR, basic metabolic panel), completes a medical history intake, then meets with a provider via video. If dapagliflozin is appropriate, the provider sends the prescription electronically to the patient's preferred Wisconsin pharmacy. The entire process, from intake to prescription, can take as few as 48 hours.

HealthRX offers telehealth consultations with providers licensed in Wisconsin who specialize in metabolic and cardiorenal conditions. Patients upload labs, complete the intake, and connect with a provider who evaluates whether dapagliflozin is clinically appropriate based on their specific diagnosis and kidney function.

Required Labs Before Starting Farxiga

Providers in Wisconsin follow the same lab requirements outlined in the Farxiga prescribing information. Baseline labs must be obtained before initiating therapy.

The minimum lab panel includes an estimated glomerular filtration rate (eGFR), serum creatinine, fasting blood glucose or HbA1c (for diabetes indications), serum potassium, and a urinalysis. Farxiga is not recommended for initiation in patients with an eGFR below 25 mL/min/1.73 m² for the diabetes indication, though the DAPA-CKD trial enrolled patients with eGFR as low as 25 mL/min/1.73 m² for the CKD indication [1]. Current labeling permits continuation in patients already taking the drug even if eGFR falls below this threshold.

A lipid panel and liver function tests are not required by the label but are commonly ordered because providers want a complete metabolic picture. Blood pressure should also be measured, since dapagliflozin produces a modest reduction in systolic BP (approximately 3 to 5 mmHg based on pooled trial data) that may require adjustment of existing antihypertensives [2].

Labs can be drawn at any Quest Diagnostics, Labcorp, or hospital-affiliated laboratory in Wisconsin. Many telehealth providers, including HealthRX, accept lab results from the past 90 days. If your labs are older, you will need a new draw before a provider can prescribe.

Wisconsin Medicaid Coverage and Prior Authorization

Wisconsin Medicaid (BadgerCare Plus and fee-for-service) covers Farxiga with prior authorization. The drug sits on the preferred drug list for type 2 diabetes, heart failure, and chronic kidney disease, but PA is mandatory for all three indications.

The prior authorization process in Wisconsin requires your prescriber to submit documentation to the Medicaid managed care organization (MCO) or to the fee-for-service PA unit. Required documentation typically includes: the specific diagnosis (ICD-10 code), current and prior medications tried, relevant lab results (HbA1c for diabetes, eGFR for CKD, ejection fraction for heart failure), and a clinical rationale for why dapagliflozin is preferred over formulary alternatives.

For the diabetes indication, most Wisconsin Medicaid MCOs require documentation that the patient has tried and failed, or has a contraindication to, metformin. For the heart failure indication, some MCOs require evidence of prior treatment with an ACE inhibitor or ARB plus a beta-blocker. The DAPA-HF trial showed that dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% compared to placebo (HR 0.74; 95% CI 0.65 to 0.85; P<0.001) in patients with heart failure and an ejection fraction of 40% or less [1]. Citing this trial in the PA submission strengthens the clinical justification.

PA decisions typically arrive within 24 to 72 hours. Denials can be appealed. Wisconsin Medicaid allows a 72-hour emergency supply while the PA is pending, so patients are not left without medication during the review.

Commercial Insurance and Employer Plans

Most commercial insurers in Wisconsin cover dapagliflozin, though formulary tier placement and copay amounts vary widely. The major Wisconsin-based plans, including Quartz, Group Health Cooperative of South Central Wisconsin, and Dean Health Plan (now Quartz), generally place Farxiga on tier 3 (preferred brand) or tier 4 (non-preferred brand).

Patients with commercial insurance may qualify for the AstraZeneca Farxiga Savings Card, which can reduce copays to as little as $0 per month for eligible patients. The savings card covers up to a maximum annual benefit (check current terms at the AstraZeneca patient assistance site). It does not apply to government-funded insurance, including Medicaid, Medicare, Tricare, or VA coverage.

For patients on Medicare Part D in Wisconsin, Farxiga is covered under most formularies, though it often requires prior authorization or step therapy. Medicare beneficiaries who hit the coverage gap should note that the Inflation Reduction Act capped out-of-pocket Part D spending at $2,000 per year starting in 2025, which significantly reduces annual Farxiga costs for many seniors [3].

Uninsured patients face retail prices between $550 and $620 for a 30-day supply. AstraZeneca's patient assistance program, AZ&Me, provides free medication to patients who meet income eligibility requirements (generally at or below 400% of the federal poverty level). Applications are processed within 4 to 6 weeks.

Wisconsin Pharmacies That Stock Farxiga

Farxiga is widely available at chain pharmacies across Wisconsin. Walgreens, CVS, Walmart, Costco, and independent pharmacies throughout the state stock the brand-name product.

Specialty pharmacy dispensing is not required for dapagliflozin. It is classified as a standard retail prescription, unlike some injectable medications that require cold-chain shipping or specialized handling. Any Wisconsin-licensed retail pharmacy can fill the prescription.

For patients in rural Wisconsin, mail-order pharmacy is a practical option. Express Scripts, OptumRx, and Caremark all dispense Farxiga via mail with standard 90-day fills. Mail-order typically costs less per unit than 30-day retail fills, and the medication ships in temperature-stable packaging.

Wisconsin-licensed 503A compounding pharmacies can compound dapagliflozin preparations. This may be relevant for patients who cannot swallow standard tablets, as a compounding pharmacy could prepare an oral suspension. The Wisconsin Pharmacy Examining Board oversees 503A compliance, ensuring these pharmacies meet USP <795> compounding standards [4].

Transferring a Farxiga Prescription to Wisconsin

Patients relocating to Wisconsin or visiting for an extended period can transfer an existing Farxiga prescription from another state. Wisconsin law allows pharmacies to accept prescription transfers from any state, and the process typically takes 15 to 30 minutes.

The patient contacts their new Wisconsin pharmacy and provides the name and location of the originating pharmacy. The receiving pharmacist calls the transferring pharmacy, verifies the prescription details, and processes the transfer. Electronic prescriptions can also be re-sent by the prescribing provider directly to the new pharmacy.

If the prescribing provider is not licensed in Wisconsin, the patient will eventually need to establish care with a Wisconsin-licensed provider for ongoing refills. Most states and Wisconsin allow a limited number of transfer fills (typically one refill or one 30-day supply) before a new prescription is required from a local provider.

Telehealth makes this transition straightforward. A patient moving from Illinois, Minnesota, or any other state can schedule a telehealth visit with a Wisconsin-licensed provider, bring their medication history and recent labs, and receive a new prescription within days.

Clinical Evidence Supporting Dapagliflozin

Dapagliflozin has one of the broadest evidence bases among SGLT2 inhibitors, spanning three distinct organ systems: metabolism, heart, and kidneys.

For type 2 diabetes, the FDA first approved dapagliflozin in January 2014. In registration trials, dapagliflozin 10 mg reduced HbA1c by 0.5% to 0.7% as monotherapy and produced mean weight loss of 2 to 3 kg over 24 weeks [5]. The DECLARE-TIMI 58 trial (N=17,160) evaluated cardiovascular outcomes in patients with type 2 diabetes and showed that dapagliflozin reduced hospitalization for heart failure by 27% compared to placebo (HR 0.73; 95% CI 0.61 to 0.88) [6].

For heart failure, the DAPA-HF trial (N=4,744) demonstrated a 26% reduction in the primary composite endpoint among patients with heart failure and reduced ejection fraction, with benefits appearing as early as 28 days after randomization [1]. Dr. John McMurray, the trial's principal investigator, stated: "The benefit of dapagliflozin was consistent irrespective of diabetes status, which changed how we think about SGLT2 inhibitors as heart failure therapies" [1].

For CKD, the DAPA-CKD trial (N=4,304) was stopped early for efficacy after a median follow-up of 2.4 years. Dapagliflozin reduced the primary composite of sustained decline in eGFR of at least 50%, end-stage kidney disease, or renal or cardiovascular death by 39% (HR 0.61; 95% CI 0.51 to 0.72; P<0.001) [7]. The KDIGO 2024 CKD guideline recommends SGLT2 inhibitors for patients with CKD and an eGFR of 20 to 45 mL/min/1.73 m², or those with eGFR 45 to 90 mL/min/1.73 m² and albuminuria.

Safety Considerations Specific to Wisconsin Patients

Dapagliflozin carries several class-wide SGLT2 inhibitor safety considerations that Wisconsin providers monitor.

The most common adverse effects include genital mycotic infections (occurring in approximately 5% to 8% of women and 2% to 3% of men), urinary tract infections, and volume depletion [5]. Wisconsin winters are dry, and indoor heating can contribute to dehydration. Providers in the state often counsel patients to maintain adequate fluid intake, particularly during the cold months when thirst cues diminish.

Diabetic ketoacidosis (DKA) is a rare but serious risk, occurring in approximately 0.1% to 0.3% of patients on SGLT2 inhibitors [8]. The risk is higher in patients with type 1 diabetes (an off-label use), those on very low-carbohydrate diets, or during acute illness. Wisconsin providers advise patients to hold dapagliflozin during any illness causing vomiting, diarrhea, or reduced oral intake. The "sick day rules" protocol is standard counseling at Wisconsin health systems.

The FDA issued a label update regarding Fournier's gangrene, an exceedingly rare necrotizing fasciitis of the perineum. Across all SGLT2 inhibitors, the FDA identified 55 cases over a 5-year pharmacovigilance period, placing the incidence well below 0.01% [9]. Providers should counsel patients to seek immediate care for any perineal pain, tenderness, or swelling.

Kidney function monitoring is recommended. Check eGFR before initiation, then periodically during treatment. The prescribing information recommends reassessing eGFR at least annually, though many Wisconsin nephrologists check every 3 to 6 months for patients with baseline CKD.

Cost Optimization Strategies for Wisconsin Residents

Several approaches can reduce out-of-pocket costs for Farxiga in Wisconsin.

The AstraZeneca Savings Card is the first option for commercially insured patients. Eligibility requires commercial insurance. Government-funded insurance disqualifies patients. The card can reduce copays substantially, sometimes to $0 per fill.

GoodRx, RxSaver, and similar discount platforms show cash prices at Wisconsin pharmacies. Prices vary by location. A Costco pharmacy in Madison or Milwaukee may offer a lower cash price than a CVS in a smaller market, though exact pricing changes frequently. Patients should compare at least three pharmacies before filling.

The AZ&Me Patient Assistance Program serves uninsured or underinsured patients. Income documentation is required. Approved patients receive Farxiga at no cost for one year, renewable annually.

For Medicare Part D beneficiaries, the $2,000 annual out-of-pocket cap means that even a high-tier copay for Farxiga becomes manageable over the plan year [3]. Patients who reach the cap early continue receiving their medications with no additional cost-sharing for the remainder of the year.

Wisconsin's SeniorCare program, a state pharmaceutical assistance program for residents aged 65 and older, may provide additional savings. Eligibility depends on income, and the program operates as a supplement to, not a replacement for, Medicare Part D. Patients enrolled in SeniorCare should check whether Farxiga is on the program's formulary.

Patients should start Farxiga at the 5 mg dose when the provider determines this is clinically appropriate. The 5 mg and 10 mg tablets are often priced identically, but beginning at the lower dose avoids overpaying if the patient responds adequately without uptitration.